Icon PLC (ICLR)
ICON provides outsourced clinical development and commercialization services to pharmaceutical, biotech and medical device companies. It last closed at $186.71 on Nov 20, down 1.92% on the day. Over the last 12 months ICLR insiders bought $0 of stock on the open market and sold $8.2M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From ICLR's SEC filings, latest 20-F for the period ending Sep 30, 2026 (filed May 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on ICLR
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 21% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the Pivot S1 at $183.34, and the nearest resistance the Pivot at $187.15.
| RSI (14) | 44.58 | Middle of its range | Neutral |
| MACD | 2.63 | Below its signal line | Bearish |
| Stochastic | 15.4 | Near the bottom of its range | Oversold |
| ADX (14) | 30.3 | Trending down | |
| Williams %R | -89.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -113.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −8.8% | Change over 10 sessions | Bearish |
| ATR (14) | $8.13 | Typical daily range, 4.4% of price |
| RSI (14) | 57.63 | Middle of its range | Neutral |
| MACD | 12.00 | Above its signal line | Bullish |
| Stochastic | 62.7 | Middle of its range | Neutral |
| ADX (14) | 30.9 | Trending up | |
| Williams %R | -51.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 97.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +10.3% | Change over 10 sessions | Bullish |
| ATR (14) | $17.92 | Typical daily range, 9.6% of price |
What happened before
See how ICLR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ICLR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in ICLR in the last 90 days.
Dark PoolPrices may be delayed
30DICLR Institutional Ownership
Full report →- ●199 buying vs 193 selling
- ▼Shares held by funds -4.8%
- ●Funds holding -2
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 424 | 426 | −0.5% |
| In funds' top 10 | 16 | 19 | −15.8% |
| Held by funds | – | – | – |
| New / increased | 45 / 154 | 83 / 147 | −13.5% |
| Reduced / sold out | 149 / 44 | 141 / 80 | −12.7% |
| Put/call ratio | 1.80 | 0.71 | +155.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
ICLR Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 12 | Ciaran MurrayDirector | Sale | 10,000 | $200.18 | $2.0M |
| Nov 2 | Ciaran MurrayDirector | Sale | 3,452 | $205.66 | $710K |
| Nov 2 | Nigel Bernard John ClerkinCFO | Sale | 1,488 | $206.66 | $308K |
| Nov 2 | Emer LyonsChief Accounting Officer | Sale | 264 | $206.66 | $55K |
| Nov 2 | Barry Edward BalfeCEO | Sale | 5,175 | $206.66 | $1.1M |
| Oct 23 | Emer LyonsChief Accounting Officer | Sale | 272 | $182.37 | $50K |
From SEC Form 4 filings by ICLR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ICLR is in one of them and how their past ICLR trades turned out.
ICLR News Tone and PricePrices may be delayed
ICLR News & Analysis
All StreetAlpha news →ICLR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Kevin HernR · OK | Sell (partial) | $15K – $50K | Aug 14, 2026 | Sep 1, 2026 | 18 d |
| Kevin HernR · OK | Sell | $100K – $250K | Mar 5, 2026 | Apr 3, 2026 | 29 d |
| Julia LetlowR · LA | Sell | $1K – $15K | Feb 12, 2026 | Mar 12, 2026 | 28 d |
| John JamesR · MI | Sell | $1K – $15K | Sep 4, 2024 | Sep 6, 2024 | 2 d |
| John JamesR · MI | Buy | $1K – $15K | Jun 12, 2024 | Sep 2, 2024 | 82 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Icon
ICON is an outsourced development and commercialization services provider based in Dublin, Ireland. It serves pharmaceutical, biotechnology, medical device, and government and public health organizations. Its services cover clinical development strategy, trial design, full study execution and commercialization of treatments. The company works across all phases of clinical development, from Phase I to Phase IV studies. Offerings also include clinical trial management, consulting, contract staffing, data solutions and laboratory services.
- Headquarters
- Dublin 18, Ireland








